Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer

NCT07492394 | Recruiting Phase 2

• 1 other identifier: OBU-BC-II-278
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Brief Summary This is an open-label, randomized, phase II clinical study designed to evaluate neoadjuvant treatment regimens in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer. A total of 60 premenopausal, perimenopausal, and postmenopausal patients with HR+/HER2- breast cancer who meet the inclusion criteria will be enrolled. During the study, clinical information will be collected according to standard practice, including demographic data, tumor imaging, and pathological results (e.g., Ki-67). Investigator-assessed outcomes will be used as the final results. After 14 days of treatment, patients who provide consent will undergo a second biopsy to evaluate the rate of complete cell-cycle arrest. Safety assessments and imaging evaluations will be performed at treatment completion or upon study withdrawal. Informed consent must be obtained at each study center before participation. Treatment arms: Arm A (30 patients): Dalpiciclib 125 mg orally once daily on Days 1-21 of each 28-day cycle (3 weeks on, 1 week off), for 6 cycles Letrozole 2.5 mg orally once daily continuously for 6 cycles Entinostat 3 mg orally once weekly (Days 1-28 of each 28-day cycle), for 6 cycles Arm B (30 patients): Dalpiciclib 150 mg orally once daily on Days 1-21 of each 28-day cycle, for 6 cycles Letrozole 2.5 mg orally once daily continuously for 6 cycles Premenopausal and perimenopausal women will also receive ovarian function suppression (OFS), such as with a GnRHa agent. After signing informed consent, patients will begin neoadjuvant therapy with dalpiciclib plus entinostat and letrozole ± OFS. Ultrasound assessments will be conducted every two treatment cycles and before surgery under the same imaging conditions as baseline. Bone scans will be performed at the end of neoadjuvant treatment. MRI of the breast will be performed at baseline, after two cycles, and before surgery to assess treatment efficacy. Treatment discontinuation will occur if toxicity is intolerable, consent is withdrawn, or the investigator determines it is necessary. Adjuvant therapy: After surgery, patients will receive physician's choice of therapy (TPC). Safety follow-up: Patients will be followed until they start another anticancer therapy, all adverse events have resolved to Grade 0-1 or baseline level, or death-whichever occurs first.

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

• ORR

  Objective Response Rate (ORR) is defined as the proportion of participants who achieve a complete response (CR) or partial response (PR) as assessed according to RECIST v1.1 criteria. Tumor response must be confirmed by repeat imaging at least 4 weeks after the initial documentation of response.

  From baseline to end of neoadjuvant therapy (approximately 6 cycles, ~24 weeks

Secondary Outcomes (3)

• tpCR

  At the time of definitive surgery (approximately 18-24 weeks after initiation of neoadjuvant therapy)

• Breast-conserving surgery (BCS) rate

  At the time of definitive surgery

• Proportion of participants achieving PEPI 0

  At the time of definitive surgery

Study Arms (2)

Dalpiciclib Plus Letrozole and Entinostat Arm

EXPERIMENTAL

Dalpiciclib: 125 mg orally once daily on Days 1-21 of each 28-day cycle (3 weeks on, 1 week off), for a total of 6 cycles. Letrozole: 2.5 mg orally once daily continuously, for a total of 6 cycles. Entinostat: 3 mg orally once weekly on Days 1-28 of each 28-day cycle, for a total of 6 cycles.

Drug: Dalpiciclib; Drug: Letrozole

Dalpiciclib Plus Letrozole Arm

PLACEBO COMPARATOR

Dalpiciclib: 150 mg orally once daily on Days 1-21 of each 28-day cycle (3 weeks on, 1 week off), for a total of 6 cycles. Letrozole: 2.5 mg orally once daily continuously, for a total of 6 cycles.

Drug: entinostat; Drug: Dalpiciclib; Drug: Letrozole

Interventions

entinostat DRUG

Entinostat is added in the experimental arm, while the control arm does not receive Entinostat.

Also known as: HDAC inhibitor

Dalpiciclib Plus Letrozole Arm

Dalpiciclib DRUG

Dalpiciclib is both added in the experimental arm and control arm.

Dalpiciclib Plus Letrozole Arm; Dalpiciclib Plus Letrozole and Entinostat Arm

Letrozole DRUG

Letrozole is both added in the experimental arm and control arm.

Dalpiciclib Plus Letrozole Arm; Dalpiciclib Plus Letrozole and Entinostat Arm

Eligibility Criteria

• Age: 18 Years - 75 Years
• Gender Eligibility Details: Postmenopausal or premenopausal/perimenopausal female patients aged ≥18 years and \<75 years.
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female patients aged ≥18 and \<75 years, including postmenopausal, premenopausal, or perimenopausal. Postmenopause is defined as:Prior bilateral oophorectomy, or age ≥60 years; orAge \<60 years, natural postmenopause (spontaneous cessation of menses for ≥12 months without other pathological or physiological cause) with estradiol (E2) and FSH in postmenopausal range; orPremenopausal or perimenopausal women willing to receive LHRH agonist (OFS) therapy during the study.
• Histologically confirmed estrogen receptor (ER)-positive (\>10%) invasive breast cancer, regardless of PR expression, and HER2-negative according to the 2018 ASCO/CAP HER2 testing guidelines (IHC 0+ or IHC 2+ with ISH-negative, amplification ratio \<2.0).
• At least one measurable lesion according to RECIST 1.1; clinical stage T1c-T2, cN1-2, or T3-T4, cN0-2.
• No prior anticancer therapy for breast cancer, including chemotherapy,endocrine therapy, or targeted therapy.
• Ability to swallow oral medications.
• Baseline left ventricular ejection fraction (LVEF) ≥50%.
• Adequate organ function:Hematology (within 1 week):Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L;White blood cell count (WBC) ≥3.0 × 10⁹/L;Platelet count ≥90 × 10⁹/L;Hemoglobin ≥90 g/L Liver and kidney function (within 1 week):Total bilirubin (TBIL) ≤ upper limit of normal (ULN);ALT and AST ≤1.5 × ULNBUN and creatinine ≤1.5 × ULN, with creatinine clearance ≥60 mL/min (Cockcroft-Gault formula)
• ECG: Corrected QT interval ≤470 ms (12-lead ECG)
• Willingness and ability to undergo all required biopsy procedures.
• Women of childbearing potential must have a negative pregnancy test before study entry and agree to use medically acceptable contraception during the study; postmenopausal women are exempt.
• Voluntary participation with signed informed consent, good compliance, and willingness to adhere to follow-up requirements.

You may not qualify if:

• Pregnant or breastfeeding women, or women with a positive pregnancy test at baseline; women of childbearing potential unwilling to use effective contraception during the study.
• Bilateral breast cancer or inflammatory breast cancer.
• Stage IV (metastatic) breast cancer at initial diagnosis.
• History of congestive heart failure, unstable angina, significant arrhythmia, or myocardial infarction.
• Active pulmonary disease, including interstitial lung disease, pneumonia, pulmonary fibrosis, or other acute lung conditions.
• Significant liver disease, such as acute or fulminant hepatitis, impaired coagulation factor synthesis, or other severe hepatic dysfunction.
• For patients positive for HBsAg or HBV core antibody, peripheral blood HBV DNA must be \<1×10³ IU/mL to be eligible.
• Any concurrent disease or condition that may interfere with study participation or affect patient safety (e.g., active or uncontrolled infection).
• Other invasive malignancies (including second primary breast cancer) that may interfere with study outcomes or compliance.
• Prior chemotherapy, endocrine therapy, or biologic therapy for breast cancer (except diagnostic biopsy for primary breast cancer).
• Major surgery within 4 weeks prior to study entry or unresolved significant medical conditions.
• Tumors that are non-measurable during the study treatment.
• Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation.

Sponsors & Collaborators

• Hebei Medical University Fourth Hospital: lead
• Jiangsu Hengrui Pharmaceutical Co., Ltd.: collaborator

Study Sites (1)

The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050000, China

RECRUITING

MeSH Terms

Conditions

Breast Neoplasms

Interventions

entinostat; Histone Deacetylase Inhibitors; dalpiciclib; Letrozole

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Nitriles; Organic Chemicals; Triazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• Zhenchuan Song

  he Fourth Hospital of Hebei Medical University

  STUDY CHAIR

Central Study Contacts

Zhenchuan Song

CONTACT

18531117857; songzhch@hotmail.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 4, 2025
• First Posted: March 25, 2026
• Study Start: September 12, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2031
• Last Updated: April 2, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)